source
- Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin marketTakeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
- Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug programWindward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…